Raffaele Giusti1, Marco Mazzotta2, Marco Filetti2, Gennaro Daniele3, Hiroaki Tsukuura4, Corrado Ficorella5, Giampiero Porzio5, Paolo Marchetti2,6, Lucilla Verna5. 1. Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy. rgiusti@ospedalesantandrea.it. 2. Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy. 3. Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy. 4. Tokyo Sakura Hospital, 1-11-1 Higashishinosaki machi, Edogawa-ku, Tokyo, Japan. 5. Medical Oncology, Department of Biotechnological and Applied Clinical Sciences, St. Salvatore Hospital, L'Aquila, Italy. 6. Medical Oncology Unit, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, Italy.
Abstract
PURPOSE: Antiemetics are being used both for the treatment and prophylaxis of opioid-induced nausea and vomiting (OINV) in clinical practice, despite the lack of evidence for the prophylactic benefit. Studies among Japanese physicians demonstrated over 80% prescribe antiemetics, with neuroleptic antipsychotics as the most commonly prescribed drugs. Our objective was to elucidate the current scenario of the prophylactic use of antiemetics for OINV among Italian physicians. METHODS: We conducted a web-based cross-sectional national survey. All the invited participants received an e-mail with an 11-item electronic questionnaire accessible through a direct link. Anonymity was guaranteed. According to the exploratory intent of the survey, we did not predefine any formal statistical hypothesis. Associations between variables were tested by the Pearson chi-square or the Fisher exact test. RESULTS: From January to March 2017, 112 completed the electronic questionnaire (112/256, overall response rate, 43.7%). Nearly half of the participants were oncologists (54; 48.2%). Sixty-one (54.4%) physicians worked in palliative care units. About 45% of the interviewed prescribed prophylactic antiemetics at the beginning of opioid prescription. The most commonly chosen drugs for this purpose were prokinetics such as metoclopramide and domperidone (84%), followed by 5-HT3 antagonists (8%), neuroleptic antipsychotics (6%), and corticosteroids (2%). Ninety-one physicians (81%) declared to prescribe antiemetics at the occurrence of OINV, mainly prokinetics (N = 70; 77%). CONCLUSION: Italian physicians do not commonly prescribe prophylactic antiemetics for OINV. Unlike previously reported data, dopamine antagonists resulted the most commonly prescribed drugs. Prospective clinical trials are necessary to evaluate the real efficacy of this practice.
PURPOSE: Antiemetics are being used both for the treatment and prophylaxis of opioid-induced nausea and vomiting (OINV) in clinical practice, despite the lack of evidence for the prophylactic benefit. Studies among Japanese physicians demonstrated over 80% prescribe antiemetics, with neuroleptic antipsychotics as the most commonly prescribed drugs. Our objective was to elucidate the current scenario of the prophylactic use of antiemetics for OINV among Italian physicians. METHODS: We conducted a web-based cross-sectional national survey. All the invited participants received an e-mail with an 11-item electronic questionnaire accessible through a direct link. Anonymity was guaranteed. According to the exploratory intent of the survey, we did not predefine any formal statistical hypothesis. Associations between variables were tested by the Pearson chi-square or the Fisher exact test. RESULTS: From January to March 2017, 112 completed the electronic questionnaire (112/256, overall response rate, 43.7%). Nearly half of the participants were oncologists (54; 48.2%). Sixty-one (54.4%) physicians worked in palliative care units. About 45% of the interviewed prescribed prophylactic antiemetics at the beginning of opioid prescription. The most commonly chosen drugs for this purpose were prokinetics such as metoclopramide and domperidone (84%), followed by 5-HT3 antagonists (8%), neuroleptic antipsychotics (6%), and corticosteroids (2%). Ninety-one physicians (81%) declared to prescribe antiemetics at the occurrence of OINV, mainly prokinetics (N = 70; 77%). CONCLUSION: Italian physicians do not commonly prescribe prophylactic antiemetics for OINV. Unlike previously reported data, dopamine antagonists resulted the most commonly prescribed drugs. Prospective clinical trials are necessary to evaluate the real efficacy of this practice.
Entities:
Keywords:
Antiemetics; Cancer pain; OINV; Opioid-induced nausea and vomiting; Prophylaxis
Authors: N Cherny; C Ripamonti; J Pereira; C Davis; M Fallon; H McQuay; S Mercadante; G Pasternak; V Ventafridda Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: J Hardy; S Daly; B McQuade; M Albertsson; V Chimontsi-Kypriou; P Stathopoulos; P Curtis Journal: Support Care Cancer Date: 2002-02-09 Impact factor: 3.603
Authors: Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis Journal: Support Care Cancer Date: 2016-08-17 Impact factor: 3.603
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976